FDA Clears First OTC Apraclonidine Drop, Alcon’s Brytly

FDA approved Alcon's Brytly on Friday, 16 October 2026, as the first nonprescription eye drop built on apraclonidine — and only the second alpha-adrenergic agonist ever cleared for over-the-counter redness relief, after Bausch + Lomb's Lumify opened the category in 2017. The approval is a narrow one on paper: a 0.125% solution, ages 12 and up, for temporary relief of redness from minor irritation. Underneath it is a switch approval, a new entrant into a category one company has owned for nine years, and a naming overlap with an existing prescription product that labeling teams will want to get ahead of.

What was approved

Apraclonidine is an alpha-2 adrenergic agonist. At the concentration and indication FDA just cleared for Brytly, it works the same way its OTC rival Lumify does: constricting the small blood vessels on the surface of the eye to reduce the appearance of redness. That mechanism is already well established in prescription ophthalmology — apraclonidine at a much higher 1% concentration is sold as Iopidine, used short-term to blunt intraocular-pressure spikes after anterior-segment laser surgery. Brytly's 0.125% strength and its consumer indication for minor-irritation redness are the new elements FDA evaluated for nonprescription use: a lower dose, a different population, and a label written for someone making the purchasing decision themselves, without a clinician reviewing the diagnosis first.

A second entrant after nine years

Bausch + Lomb's Lumify, approved for over-the-counter sale in December 2017, built the modern alpha-agonist redness-relief category and has not had a direct mechanistic competitor since. Older OTC redness relievers rely on different vasoconstrictors with a longer-documented rebound-redness problem on withdrawal; Lumify's selling point was a lower rebound risk at its approved dose. Brytly enters on the same alpha-agonist logic with a different molecule, which means retailers, pharmacists, and the sponsors of both products will be litigating the same comparative-efficacy and rebound-redness questions in advertising and on shelf messaging that Lumify spent years establishing largely unchallenged.

FDA's own framing of the approval leaned on access rather than competition. CDER Director Michael Davis, confirmed permanently in the role on 8 September 2026, said in the agency's statement that expanding access to safe, effective nonprescription treatments is a priority for the agency, giving consumers a way to manage eye redness without first seeing a health care provider. That access framing is consistent with FDA's broader Nonprescription Safe Use Regulatory Expansion (NSURE) push to move more self-selectable conditions out of the prescription-only lane — Brytly is a data point in that policy, not an isolated switch.

The look-alike risk regulatory teams should flag

Apraclonidine now exists on US shelves in two concentrations, under two brand names, for two different purposes: Iopidine 1%, prescription-only, for short-term postoperative intraocular-pressure control; and Brytly 0.125%, nonprescription, for everyday redness. Same active ingredient, an eightfold difference in concentration, and label instructions that do not transfer between them. That is exactly the setup pharmacovigilance teams watch for look-alike/sound-alike dispensing and self-selection errors, and it argues for clear differentiation in packaging and point-of-sale placement rather than relying on the Rx/OTC status line alone to do the work. Persistent or worsening redness, FDA's messaging around the approval notes, can also signal a condition that needs medical evaluation — a standard OTC-ophthalmic caution that matters more, not less, when a second active ingredient enters a category a consumer may assume is interchangeable.

Frequently asked questions

What did FDA approve, and when?

On Friday, 16 October 2026, FDA approved Brytly, Alcon's apraclonidine ophthalmic solution 0.125%, as a nonprescription treatment for temporary relief of eye redness caused by minor irritation, such as dryness or exposure to dust. It is the first nonprescription eye drop containing apraclonidine.

Who can use it, and how often?

Brytly is labeled for adults and children aged 12 years and older. Reporting on the approval describes a maximum of two applications per day; sponsors and pharmacists should confirm exact frequency and duration-of-use limits against Alcon's final Drug Facts label.

How is this different from prescription apraclonidine?

Prescription apraclonidine is sold at a higher, 1% concentration as Iopidine, commercialized by Harrow since June 2022, and is used for short-term control of intraocular pressure spikes after anterior-segment laser procedures — an entirely different use case from OTC redness relief. Brytly's 0.125% concentration and consumer indication are new; the shared active ingredient and similar naming create a look-alike/sound-alike risk pharmacists and labeling reviewers should note.

Why does this matter beyond one product?

Bausch + Lomb's Lumify, approved for OTC use in 2017, has had the modern alpha-agonist redness-relief category largely to itself for nearly a decade. Brytly is a second entrant with a different active ingredient and the same mechanism, and FDA's own framing of the approval, through CDER Director Michael Davis, ties it to a broader agency push to expand nonprescription options.